Dual Tasking Training to Enhance Self-Efficacy in Individuals With Parkinson's Disease
NCT07611578, Not applicable, Recruiting, Alvaro Reyes
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Dual Tasking Training to Enhance Self-Efficacy in Individuals With Parkinson's Disease | ClinicalTrials.gov |
| NCT number | NCT07611578 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 112 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Alvaro Reyes | ClinicalTrials.gov |
| Conditions | Parkinson´s Disease | ClinicalTrials.gov |
| Interventions | dual tasking training | ClinicalTrials.gov |
| First posted | 2026-05-28 | ClinicalTrials.gov |
| Last updated | 2026-10-30 | ClinicalTrials.gov |
Registered outcomes 11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Self-efficacy (The Latin Spanish version of the Self-Efficacy to Manage Chronic Disease for the Chilean population ) | From enrollment to the end of treatment at 8 weeks | Self-efficacy is the perceived ability to perform specific tasks to achieve concrete goals successfully. The Latin Spanish version of the Self-Efficacy to Manage Chronic Disease for the Chilean population (SEMCD-S) will be used for this outcome. In the SEMCD-S, participants rank each one of the 4 items from 0 to 10. Higher scores indicate higher self-efficacy. | ClinicalTrials.gov |
| Primary | Self-efficacy (General Self-Efficacy Scale) | From enrollment to the end of treatment at 8 weeks | Self-efficacy is the perceived ability to perform specific tasks to achieve concrete goals successfully. The General Self-Efficacy scale (GSES) will be used for this outcome. In the GSES, participants rank each one of the 10 items from 0 to 7. Higher scores indicate higher self-efficacy. | ClinicalTrials.gov |
| Primary | Unified Parkinson's Disease Rating Scale (revised version) | From enrollment to the end of treatment at 8 weeks | The sections II and III of the Unified Parkinson's Disease Rating Scale (revised version) will be used to analyse the effect of the intervention on activities of daily life and clinical motor aspects of the disease. The scale ranks from 0 to 199. Higher score indicates worse performance. | ClinicalTrials.gov |
| Primary | Balance | From enrollment to the end of treatment at 8 weeks | Static and dinamic balance during functional activities will be measured using the Mini Best Test.The Mini BesTest has demonstrated to be valid and reliable clinical measure for assessing static and dinamic balance in individuals with Parkinson's disease. The test ranks from 0 to 28 points.Higher scores indicates better performance | ClinicalTrials.gov |
| Primary | Gait (walking speed) | From enrollment to the end of treatment at 8 weeks | Spatiotemporal gait parameters under single and dual-task conditions will be measured using a pressure-sensitive mat. During the single-task condition, participants will be asked to walk at a self-selected walking speed covering 10 meters. Under dual-task condition, participants will be asked to perform the same as above while performing cognitive tasks. Walking speed (m/s) will be recorded for analysis | ClinicalTrials.gov |
| Primary | Cognitive function | From enrollment to the end of treatment at 8 weeks | The Serial Threes Test (STT) and the visual Stroop task will be used to evaluate cognitive functions under single and dual-task conditions. The STT requires participants to make multiple subtractions of three from a whole three-digit number, e.g., 256, 253, 250, 247. Different three-digit numbers will be used for each trial to reduce the learning effect. The visual Stroop task will require participants to respond (click on a computer mouse) to congruent and incongruent stimuli presented on a screen. The words "left" or "right" will be displayed on a TV screen, and participant will be asked to ignore the spatial position on the screen and instead indicate its semantic content by click. The STT and the visual Stroop task will be used because they are demonstrated to be sensitive to detect changes as well as feasible, reliable, and valid during dual tasking in individuals with PD. Number of correct responses will be recorder for further analysis and calculate single and dual task cost. | ClinicalTrials.gov |
| Primary | Brain activity of the Prefrontal cortex | From enrollment to the end of treatment at 8 weeks | The hemodynamic activity of the prefrontal and motor cortices will be measured using a functional Near-Infrared Spectroscopy system under single and dual-task conditions. A head cap containing two light emitters and detectors (devices) will be placed on the scalp on the right and left side of the forehead of each participant. In the sagittal plane, both detectors will be placed at a distance of 15% of the length of the nasion-inion starting from the nasion. In the transverse plane each detector will be placed 7% of the head circumference starting from the midline. The devices will be protected against ambient light using a black cloth covering the entire forehead. Raw data will be converted to relative changes in oxygenated and deoxygenated haemoglobin concentrations using the modified Lambert-Beer law. | ClinicalTrials.gov |
| Primary | Dual task cost | From enrollment to the end of treatment at 8 weeks | Dual-task cost values will be calculated to compare the performance on dual task modality using the following formula: dual task cost (%)=((dual task performance-single task performance)/single task performance)\*100. Negative values indicate deteriorated performance in the dual task relative to the single task. Positive values indicates a relative improvement relative to the single task. | ClinicalTrials.gov |
| Primary | Difficulties associated with Parkinson's disease | From enrollment to the end of treatment at 8 weeks | How often individuals with Parkinson's disease expereince difficulties will be measured using the Spanish version of the Parkinson's disease questionnaire (PDQ-39). This instrument includes 39 questions distributed in eight domains where 0% is no problem and 100% is maximum level of problem.This instrument has an official version for Chilean population. | ClinicalTrials.gov |
| Secondary | Gait (stride length) | From enrollment to the end of treatment at 8 weeks | Spatiotemporal gait parameters under single and dual-task conditions will be measured using a pressure-sensitive mat. During the single-task condition, participants will be asked to walk at a self-selected walking speed covering 10 meters. Under dual-task condition, participants will be asked to perform the same as above while performing cognitive tasks. Stride length (cm) will be recorded for analysis | ClinicalTrials.gov |
| Secondary | Gait (cadence) | From enrollment to the end of treatment at 8 weeks | Spatiotemporal gait parameters under single and dual-task conditions will be measured using a pressure-sensitive mat. During the single-task condition, participants will be asked to walk at a self-selected walking speed covering 10 meters. Under dual-task condition, participants will be asked to perform the same as above while performing cognitive tasks. Cadence (steps/min) will be recorded for analysis | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)